Patents Examined by Dana Shin
  • Compositions and methods for immunostimulatory RNA oligonucleotides
    Patent number: 8815503
    Abstract: The present invention provides 4-nucleotide (4mer) RNA motifs that confer immunostimulatory activity, in particular, IL-12-inducing activity to a single-stranded RNA oligonucleotide. The present invention also provides single-stranded RNA oligonucleotides, including antisense RNA, with high or low immunostimulatory activity. The present invention further provides the use of the RNA oligonucleotides of the invention for therapeutic purposes.
    Type: Grant
    Filed: September 14, 2006
    Date of Patent: August 26, 2014
    Assignee: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Gunther Hartmann, Veit Hornung
  • Stabilized immune modulatory RNA (SIMRA) compounds for TLR7 and TLR8
    Patent number: 8759310
    Abstract: The invention relates to the therapeutic use of stabilized oligoribonucleotides as immune modulatory agents for immune therapy applications. Specifically, the invention provides RNA based oligoribonucleotides with improved nuclease and RNase stability and that have immune modulatory activity through TLR7 and/or TLR8.
    Type: Grant
    Filed: January 19, 2012
    Date of Patent: June 24, 2014
    Assignee: Idera Pharmaceuticals, Inc.
    Inventors: Ekambar R. Kandimalla, Tao Lan, Yukui Li, Dong Yu, Daqing Wang, Mallikarjuna Reddy Putta, Sudhir Agrawal
  • Treatment of immune disorders with Hom-1 inhibitors
    Patent number: 8741865
    Abstract: Disclosed are methods for treating immune disorders using inhibitors of Hom-1. The inhibitors include an RNAi agent containing the sequence of SEQ ID NO: 6.
    Type: Grant
    Filed: July 15, 2010
    Date of Patent: June 3, 2014
    Inventors: Zhenglun Zhu, Hong Gao
  • Antisense oligonucleotides against cPLA, compositions and uses thereof
    Patent number: 8735368
    Abstract: Antisense oligonucleotides against cPLA2 are provided, which are capable of inhibiting cPLA2 expression as well as superoxide production, especially in phagocytes. These antisense oligonucleotides are powerful agents for the treatment of inflammatory conditions, in particular arthritis, as well as in neurodegenerative diseases. The antisense oligonucleotides or compositions comprising the same may be used in methods of treatment of such diseases.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: May 27, 2014
    Assignees: Mor Research Applications Ltd., Ben-Gurion University of the Negev Research and Development Authority
    Inventor: Rachel Levy
  • Compositions for RNA interference and methods of use thereof
    Patent number: 8729036
    Abstract: The present invention provides compositions for RNA interference and methods of use thereof. In particular, the invention provides single-stranded small interfering RNAs. Functional and genomic and proteomic methods are featured. Therapeutic methods are also featured.
    Type: Grant
    Filed: August 7, 2003
    Date of Patent: May 20, 2014
    Assignee: University of Massachusetts
    Inventors: Phillip D. Zamore, György Hutvágner, Dianne Schwarz, Guiliang Tang, Benjamin Haley
  • Methods for the modulation of angiogenesis
    Patent number: 8722638
    Abstract: The present invention relates to methods and compositions for promoting or inhibiting capillary endothelial (CE) cell migration, promoting or inhibiting the formation of CE networks and promoting or inhibiting angiogenesis. Some embodiments relate to methods and compositions for treating angiogenesis-related disorders characterized by loss or decreased angiogenesis. One aspect relates to the use of at least one pro-angiogenic agent selected from at least one of an p190RhoGAP inhibitor, a TFII-I inhibitor or a GATA-2 activator for promoting the formation of CE networks and angiogenesis, and methods for treating angiogenesis-related disorders characterized by loss or decreased angiogenesis.
    Type: Grant
    Filed: June 19, 2009
    Date of Patent: May 13, 2014
    Assignee: Children's Medical Center Corporation
    Inventors: Donald E. Ingber, Akiko Mammoto
  • Cofilin knockdown host cells and uses thereof
    Patent number: 8722409
    Abstract: The present invention relates to a host cell comprising a cofilin-specific small interfering RNA (siRNA) sequence. The host cell may further comprise a nucleic acid encoding a recombinant protein. The present invention also relates to a method for producing a recombinant protein by the host cell comprising a cofilin-specific small interfering RNA (siRNA) sequence.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: May 13, 2014
    Assignee: University of Delaware
    Inventors: Kelvin H. Lee, Stephanie Hammond
  • Agent for targeting c-Jun mRNA
    Patent number: 8686128
    Abstract: The present invention provides a method of preventing or reducing restenosis, neointima formation, graft failure, atherosclerosis, angiogenesis and/or solid tumor growth in a subject. The method comprises administering to the subject a prophylactically effective dose of a nucleic acid which decreases the level of c-Jun mRNA, c-Jun mRNA translation or nuclear accumulation or activity of c-Jun. It is preferred that the nucleic acid is a DNAzyme that targets c-Jun mRNA.
    Type: Grant
    Filed: July 12, 2012
    Date of Patent: April 1, 2014
    Inventor: Levon Michael Khachigian
  • Modulation of innate immunity receptors' signaling by microRNAs miR-146a and miR-146b
    Patent number: 8669235
    Abstract: The present disclosure relates to the finding that microRNA-146 plays a role modulating the innate immune response. Innate immunity receptor signaling can be modulated by delivery of microRNA-146 (miR-146) or antisense miR-146 to target immune cells. In some embodiments, IL-1 receptor associated kinase 1 (IRAK1) and TNF receptor associated factor 6 (TRAF6) expression levels are downregulated in a target cell by administering a miR-146 oligonucleotide. Modulation of the innate immune system through miR-146 can be used to treat a variety of diseases and disorders associated with activation of the innate immune system, such as sepsis and Crohn's disease.
    Type: Grant
    Filed: March 22, 2007
    Date of Patent: March 11, 2014
    Assignee: California Institute of Technology
    Inventors: David Baltimore, Mark Boldin, Konstantin Taganov
  • Compositions and methods for inhibiting expression of factor V
    Patent number: 8658782
    Abstract: The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the Factor V Leiden mutant gene (Factor V Leiden mutant gene), comprising an antisense strand having a nucleotide sequence which is less that 25 nucleotides in length and which is substantially complementary to at least a part of the Factor V Leiden mutant gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by the expression of the Factor V Leiden mutant gene using the pharmaceutical composition; and methods for inhibiting the expression of the Factor V Leiden mutant gene in a cell.
    Type: Grant
    Filed: January 20, 2011
    Date of Patent: February 25, 2014
    Assignee: Alynylam Pharmaceuticals, Inc.
    Inventors: Hans-Peter Vornlocher, John M. Maraganore
  • Nucleic acid capable of binding to immunoglobulin G and use thereof
    Patent number: 8637656
    Abstract: The present invention provides a novel aptamer for IgG and a method for utilizing the same and the like. More specifically, the present invention provides an aptamer that binds to an Fc region of IgG (e.g., human IgG); a complex comprising an aptamer and a functional substance bound thereto (e.g., affinity substance, labeling substance, enzyme, drug, toxin, drug delivery vehicle); a solid phase carrier with an aptamer or complex immobilized thereon; medical equipment comprising a solid phase carrier; a method for antibody purification comprising adsorbing an IgG antibody to a solid phase carrier, and eluting the adsorbed IgG antibody with an eluent; a method for producing a purified antibody, comprising preparing an IgG antibody and purifying the prepared IgG antibody with a solid phase carrier and the like.
    Type: Grant
    Filed: July 5, 2006
    Date of Patent: January 28, 2014
    Assignee: Ribomic Inc.
    Inventors: Yoshikazu Nakamura, Shin Miyakawa
  • Sensitizing agents for cancer therapy, methods of use and methods for the identification thereof
    Patent number: 8637481
    Abstract: There is provided herein methods, compounds and methods for identifying compounds, for sensitizing a subject with cancer to a cancer therapy by inhibiting or down-regulating UROD.
    Type: Grant
    Filed: April 12, 2010
    Date of Patent: January 28, 2014
    Assignee: University Health Network
    Inventors: Fei-Fei Liu, Emma Ito, Inki Kim
  • Methods for collecting and detecting oligonucleotides
    Patent number: 8614057
    Abstract: Methods, pharmaceutical compositions, and kits are provided which includes accurately sampling a RNA from a tissue of an animal and analyzing RNA in the tissue of the animal as an indicator of physiological state, infectious disease, neoplastic disease, autoimmune disease, inflammatory disease, cardiovascular disease, atherosclerotic disease, or neurological disease in the animal. A method is provided which includes administering at least one compound to an animal wherein the at least one compound is configured to prevent the cleavage of at least one tissue RNA by a ribonuclease. The method further includes collecting a sample of at least a portion of tissue from the animal.
    Type: Grant
    Filed: September 5, 2008
    Date of Patent: December 24, 2013
    Assignee: The Invention Science Fund I, LLC
    Inventors: Paul G. Allen, Edward S. Boyden, Roderick A. Hyde, Muriel Y. Ishikawa, Stephen L. Malaska, Dennis J. Rivet, Leif T. Stordal, Lowell L. Wood, Jr.
  • Modulation of exportin 5 expression
    Patent number: 8614310
    Abstract: Compounds, compositions and methods are provided for modulating the expression of exportin 5. The compositions comprise oligonucleotides, targeted to nucleic acid encoding exportin 5. Methods of using these compounds for modulation of exportin 5 expression and for diagnosis and treatment of diseases and conditions associated with expression of exportin 5 are provided.
    Type: Grant
    Filed: December 19, 2011
    Date of Patent: December 24, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventor: Kenneth W. Dobie
  • Protein-responsive RNA control devices and uses thereof
    Patent number: 8604176
    Abstract: The invention described herein relates to an RNA-based control device that senses the presence and/or concentration of at least one protein ligand, preferably through its protein-binding aptamer domain, and regulates a target gene expression through alternative splicing of the target gene in which the RNA-based control device is integrated. The device has uses in therapeutic as well as diagnostic applications.
    Type: Grant
    Filed: November 10, 2010
    Date of Patent: December 10, 2013
    Assignee: California Institute of Technology
    Inventors: Christina D. Smolke, Stephanie J. Culler
  • Micro-RNA's that regulate muscle cells
    Patent number: 8592384
    Abstract: The present invention describes microRNAs that regulate the differentiation, proliferation and death of cardiac and skeletal muscles cells. These molecules represent unique targets in the developmental pathways of muscle cells. They also can be used as active agents to induce differentiation in progenitor cells, and their down-regulation permits the maintenance and expansion of progenitor cell populations.
    Type: Grant
    Filed: April 4, 2006
    Date of Patent: November 26, 2013
    Assignee: The Board of Regents of the University of Texas System
    Inventor: Deepak Srivastava
  • Therapy of p53 mutant colon adenocarcinoma, breast cancer and lung cancer
    Patent number: 8586557
    Abstract: The present invention provides a method for treating a hyperproliferative disorder characterized by expression of a mutant form of p53 in a subject, the method comprising administering to the subject a therapeutically effective amount of an agent which inhibits promyelocytic leukemia (PML) protein.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: November 19, 2013
    Assignee: Peter MacCallum Cancer Institute
    Inventors: Ygal Haupt, Susan Haupt
  • Methods of modulating mesenchymal stem cell differentiation
    Patent number: 8580757
    Abstract: The present disclosure includes compositions and methods for modulating the differentiation of cells having osteogenic differentiation potential (such as mesenchymal stem cells (MSCs)) towards the osteogenic fate, and for obtaining diagnostic and prognostic information relating to diseases and disorders characterized by defects in osteogenic differentiation. The compositions include miRNAs, rm?RNA mimics, miRNA inhibitors, and siRNAs.
    Type: Grant
    Filed: August 7, 2008
    Date of Patent: November 12, 2013
    Assignee: Thermo Fisher Scientific Biosciences Inc.
    Inventors: Yuriy Federov, Devin Leake
  • Short oligomer antagonist compounds for the modulation of target mRNA
    Patent number: 8580756
    Abstract: The invention provides LNA gapmer oligomers of between 10-20 nucleobases in length, which have a total of 1-3 phosphodiester internucleoside linkages. Such oligomers have been found to have superior bioavailability and have also been found to selectively accumulate in kidney cells.
    Type: Grant
    Filed: March 19, 2008
    Date of Patent: November 12, 2013
    Assignee: Santaris Pharma A/S
    Inventors: Jens Bo Rode Hansen, Henrik Orum, Henrik Frydenlund Hansen, Ellen Marie Straarup, Niels Fisker Nielsen, Maj Hedtjärn
  • Double stranded constructs comprising one or more short strands hybridized to a longer strand
    Patent number: 8569474
    Abstract: The present invention provides compositions comprising an antisense oligomeric compound hybridized to at least one shorter sense oligomeric compound. The sense oligomeric compounds can be covalently linked to the antisense oligomeric compounds. At least a portion of the antisense oligomeric compound is complementary to and hybridizes with a nucleic acid target. Methods for modulating gene expression are also provided using the compositions of the present invention.
    Type: Grant
    Filed: March 4, 2005
    Date of Patent: October 29, 2013
    Assignee: Isis Pharmaceuticals, Inc.
    Inventors: Brenda F. Baker, Bryan A. Kraynack